Assertio Holdings, Inc.
NASDAQ:ASRTDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $151.86M
- Beta
- 0.53
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$5.55
Volume 0.27M
Average 0.33M
ASRT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Assertio Holdings, Inc.NASDAQ: ASRT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 3.7% from a year ago
Cash & equivalents stood at $33.71M at the end of Q1 FY2026, down 3.7% from a year earlier and up 229.6% from the prior quarter. Over 3 fiscal years it compounded at -46.0% a year.
Context
- Cash & equivalents amounted to 16.0% of total assets at the end of Q1 FY2026, up 3.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -3.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 10.23M USD
- Year-over-year change
- -79.8%
- 4-year CAGR
- -27.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.23M | -79.8% |
| FY2024 | 2024-12-31 | 50.59M | -31.1% |
| FY2023 | 2023-12-31 | 73.44M | +13.1% |
| FY2022 | 2022-12-31 | 64.94M | +76.4% |
| FY2021 | 2021-12-31 | 36.81M | — |
Cash & Equivalents vs competitors
How ASRT compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -3.7% is the 4th highest of 10, against a peer median of -16.9%.
- Cash & equivalents amounts to 16.0% of total assets for ASRT, versus a peer median of 51.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $255.84M USD | +180.1% | -23.6% | 71.7% | |
| Mar 2026 | $128.06M USD | -16.9% | +8.3% | 63.4% | |
| Mar 2026 | $115.46M USD | -25.9% | -7.2% | 82.6% | |
| Mar 2026 | $61.57M USD | -17.4% | -11.7% | 51.3% | |
| Mar 2026 | $50.75M USD | +76.8% | +6.9% | 28.2% | |
| Dec 2025 | ₪46.47M ILS | -40.7% | -41.5% | 6.7% | |
| Mar 2026 | $39.13M USD | -23.8% | -29.5% | 40.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M USD | -13.0% | +12.0% | 31.6% |
| Mar 2026 | $33.71M USD | -3.7% | -46.0% | 16.0% | |
| Apr 2026 | $4.01M USD | +35.2% | +32.1% | 58.1% | |
| Peer median (excluding ASRT) | — | -16.9% | -7.2% | 51.3% | |
Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36.81M | 64.94M | 73.44M | 50.59M | 10.23M |
| Short-term Investments | 0 | 0 | 0 | 49.47M | 53.18M |
| Net Receivables | 43.75M | 45.36M | 47.66M | 54.12M | 120.11M |
| Inventory | 7.49M | 13.7M | 37.69M | 38.31M | 24.12M |
| Other Current Assets | 608K | 0 | 299K | 10.07M | 9.01M |
| Total Current Assets | 103.5M | 132.26M | 171.06M | 202.55M | 216.65M |
| Property, Plant & Equipment (Net) | 2.26M | 881K | 2.04M | 1.71M | 444K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 216.05M | 198M | 111.33M | 80.47M | 48.91M |
| Long-term Investments | 1.58M | 268K | 0 | 0 | 0 |
| Tax Assets | 0 | 80.2M | 0 | 0 | 0 |
| Other Non-current Assets | 3.15M | 2.3M | 1.99M | 1K | 972K |
| Total Non-current Assets | 223.05M | 281.65M | 115.36M | 82.18M | 50.32M |
| Total Assets | 326.55M | 413.91M | 286.42M | 284.73M | 266.97M |
| Account Payables | 6.69M | 5.99M | 13.44M | 14.74M | 9.01M |
| Short-term Debt | 12.17M | 470K | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 47.65M | 30.37M | 6.09M | 96.36M | 118.5M |
| Total Current Liabilities | 135.02M | 95.32M | 93.44M | 114.69M | 127.51M |
| Long-term Debt | 61.32M | 66.4M | 38.21M | 38.81M | 39.12M |
| Deferred Tax Liabilities | 0 | 4.27M | 4.55M | 0 | 2.42M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 27.4M | 22.2M | 10.74M | 9.03M | 3.08M |
| Total Non-current Liabilities | 89.11M | 92.87M | 54.97M | 48.96M | 45.51M |
| Total Liabilities | 224.13M | 188.19M | 148.42M | 163.65M | 173.02M |
| Common Stock | 4K | 5K | 9K | 9K | 1K |
| Retained Earnings | (429.23M) | (319.6M) | (651.54M) | (673.12M) | (703.5M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 1 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 102.41M | 225.73M | 138M | 121.08M | 93.95M |
| Total Debt | 75.87M | 66.87M | 39.68M | 40.27M | 40.01M |
| Net Debt | 39.06M | 1.93M | (33.77M) | (10.32M) | 29.78M |
Assertio Holdings, Inc.
NASDAQ:ASRT
Intrinsic Alpha fair value
Locked
Current Price
$23.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.